Dr Muhammad Abdul Rehman Khan, Dr Usman Tariq, Dr Hafiz Muhammad Ishfaq
An assessment of a quick versatile gold-nanotechnology estimating SARS-CoV-2 IgM, IgA and IgG counter acting agent focuses against spike 1, spike 2 and nucleocapsid remained led utilizing serum tests from 76 patients tried for SARS-CoV-2 RNA on admission to medical clinic, in addition 48 recorded control cases from March 2019. 65 cases remained RNA (+) and 16 remained RNA (−). Our current research was conducted at Jinnah Hospital, Lahore form March 2020 to July 2020. A serum (±) arrangement remained inferred for each of the four antigens and the quantitative serological profile was gotten. Serum(+) remained recognized in 35% (96% CI 12–49) of at first RNA(−) cases, in 37% (96% CI 18–56) of RNA(+) cases before 16 days, 78% (96% CI 68–89) somewhere in the range of 13 and 25 days and (96% CI 87–100) following 23 days. The patient level symptomatic exactness comparative with RNA (±) following 10 days showed 89% affectability (96% CI 76–96) and 75% explicitness (96% CI 23–99), in spite of the fact that particularity contrasted and verifiable controls was 100% (98%CI 91–100). This examination offers vigorous help for additional assessment and approval of the current novel innovation in the medical setting and features difficulties characteristic in evaluation of serological tests for a developing infection, for example, COVID-19. Keywords: Real world testing, Covid-19, Antibodies.